SHC:NSD-Sotera Health Co (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 16.76

Change

0.00 (0.00)%

Market Cap

USD 4.75B

Volume

1.11M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems. The company also provides microbiological and analytical chemistry testing, as well as technical assistance, regulatory consulting, and advisory services. It serves medical devices, pharmaceuticals, food safety, agricultural products, cancer treatment, and high-performance materials industries, as well as commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-28 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 42.12B
ICLR ICON PLC

N/A

USD 23.70B
ILMN Illumina Inc

N/A

USD 20.90B
NTRA Natera Inc

N/A

USD 15.55B
EXAS EXACT Sciences Corporation

N/A

USD 12.56B
MEDP Medpace Holdings Inc

N/A

USD 10.28B
RDNT RadNet Inc

N/A

USD 5.13B
NEOG Neogen Corporation

N/A

USD 3.61B
GH Guardant Health Inc

N/A

USD 3.09B
TWST Twist Bioscience Corp

N/A

USD 2.72B

ETFs Containing SHC

IUKP:SW iShares UK Property UCITS.. 3.78 % 0.00 %

N/A

USD 0.62B
UKPH:XETRA iShares UK Property UCITS.. 3.70 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.53% 46% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.53% 46% F 41% F
Trailing 12 Months  
Capital Gain 11.88% 49% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.88% 49% F 53% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -8.41% N/A N/A 27% F
Dividend Return -8.41% N/A N/A 27% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 35.83% N/A N/A 52% F
Risk Adjusted Return -23.46% N/A N/A 26% F
Market Capitalization 4.75B 84% B 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector